NVIDIA's exit from its Recursion Pharmaceuticals equity position weighed on sentiment, though the technical collaboration is ...

As the program engages more directly with global concerns such as the climate crisis, he will lead the way.

T-cell engager (TCE) specialist Candid Therapeutics has entered a reverse merger agreement with Rallybio that will allow Candid to trade on the Nasdaq while dumping RallyBio’s rare disease maternal ...